AKERO THERAPEUTICS IN
23.50
25-June-24 15:59:58
15 minutes delayed
Stocks
-0.35
-1.47%
Today's range
23.31 - 23.99
ISIN
N/A
Source
NASDAQ
-
19 Sep 2022 16:01:00 By Nasdaq GlobeNewswire
-
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
14 Sep 2022 20:07:00 By Nasdaq GlobeNewswire
-
Akero Therapeutics Announces Proposed Public Offering of Common Stock
13 Sep 2022 16:01:00 By Nasdaq GlobeNewswire
-
13 Sep 2022 06:00:00 By Nasdaq GlobeNewswire
-
08 Sep 2022 16:01:00 By Nasdaq GlobeNewswire
-
24 Aug 2022 08:00:01 By Nasdaq GlobeNewswire
-
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
04 Aug 2022 16:05:37 By Nasdaq GlobeNewswire
-
16 Jun 2022 07:00:00 By Nasdaq GlobeNewswire
-
Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH
13 Jun 2022 08:00:01 By Nasdaq GlobeNewswire
-
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
01 Jun 2022 16:05:00 By Nasdaq GlobeNewswire
-
Akero Therapeutics Reports First Quarter 2022 Financial Results
06 May 2022 07:00:00 By Nasdaq GlobeNewswire
-
Akero Therapeutics to Present at Upcoming Healthcare Conferences in May
02 May 2022 07:30:00 By Nasdaq GlobeNewswire
-
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
25 Feb 2022 07:00:00 By Nasdaq GlobeNewswire
-
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients
08 Feb 2022 08:00:03 By Nasdaq GlobeNewswire
-
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 Jan 2022 16:05:00 By Nasdaq GlobeNewswire
-
Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference
26 Nov 2021 17:28:49 By Nasdaq GlobeNewswire
-
Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
12 Nov 2021 07:00:02 By Nasdaq GlobeNewswire
-
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
09 Nov 2021 16:15:00 By Nasdaq GlobeNewswire